Conbercept - Chengdu Kanghong Biological Science & Technology

Drug Profile

Conbercept - Chengdu Kanghong Biological Science & Technology

Alternative Names: KH902; Recombinant human VEGF receptor-Fc fusion protein

Latest Information Update: 13 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chengdu Kanghong Biological Science & Technology
  • Class Eye disorder therapies; Recombinant fusion proteins
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Wet age-related macular degeneration
  • Phase III Choroidal neovascularisation; Diabetic macular oedema; Retinal oedema

Most Recent Events

  • 04 Jul 2018 Chengdu Kanghong Biotech plans the phase III PANDA-1 trial for Age-related macular degeneration in the US (NCT03577899)
  • 01 Sep 2017 Chengdu Kanghong Biotech completes the phase II FALCON trial for Retinal oedema in China (Intravitreal) (NCT01809236)
  • 02 Sep 2015 The phase III SHINY trial for Choroidal neovascularisation is ongoing in China (NCT01809223)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top